Authors
Jia Ke, Shiyi Yu, Hong Yuan, Fuqiang Hu
Published in
Materials today. Bio. Volume 41. Pages 103806. Epub Nov 03, 2026.
Abstract
The defective hydrogen sulfide (H2S) metabolism in brain has emerged as a crucial pathogenic event and therapeutic target in Parkinson's disease (PD). However, current H2S delivery approaches for PD remain predominantly limited by the blood-brain barrier (BBB) and on-demand supply. This work aimed to upgrade the delivery of H2S to across BBB, thereby adequately harnessing its neuroprotective effect in PD brain. We developed a brain-penetrating, ROS-responsive H₂S nanocarrier (RVG29/TK@Lip/GYY) for targeted H₂S delivery in the PD brain. In this system, the H₂S donor GYY4137 was encapsulated within the liposomal core, and a ROS-responsive thioketal (TK) linker was incorporated into the lipid bilayer to enable on-demand H₂S release in the oxidative PD microenvironment. The liposomal surface was modified with the brain-homing peptide RVG29 to facilitate BBB crossing and neuronal targeting. This formulation achieved a good BBB penetration rate of 22.12%. In addition, pathological evaluation demonstrated that the controlled H2S release by RVG29/TK@Lip/GYY exerted multiple PD pathogenic interventions, including scavenging excessive ROS, alleviating nitrative stress, decreasing neuronal apoptosis, suppressing glial cell activation, and promoting nerve regeneration. Importantly, RVG29/TK@Lip/GYY treatment significantly attenuated the motor deficits of PD model mice. Collectively, this study not only provides a promising H2S nanocarrier for PD multiple pathological therapy, but also contributes to the development of H2S delivery in other neurodegenerative diseases treatment.
PMID:
43034870
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0